Designed for the changing healthcare landscape.

Precision Medicine Group was founded in 2012 to transform the process of bringing new drugs to market by integrating science, technology, data, and human expertise. We invest organically and acquire capabilities to address the fundamental changes in healthcare necessary for global health and outcomes improvement.

Our Co-founders

Mark Clein and Ethan Leder are experienced entrepreneurs with a 30-year history of creating cutting-edge businesses in the healthcare industry, producing thousands of jobs and significant value for shareholders. Since co-founding Precision Medicine Group, the company has grown to over 3200 employees around the world, all dedicated to the mission of accelerating development and access to breakthrough treatments to improve the lives of patients in need.


Chief Executive Officer,
Precision Medicine Group


Executive Chairman,
Precision Medicine Group

Precision Medicine Group Board of Directors

Our board of directors has deep knowledge of the biotech and pharma industry and rich insights on the capabilities required to bring the next generation of novel therapies to market.

Anushka Sunder

Senior Managing Director and Head of Healthcare Private Equity North America, Blackstone

Chris Hadley

Managing Director, Berkshire Partners

Fred Cohen, MD

Co-Founder and Chairman at Monograph Capital Partners and Co-Founder and Senior Managing Director at Vida Ventures

John Hubbard, PhD

Chairman of the Precision Medicine Group Board of Directors

Matt Hobart

Co-Managing Partner, TPG Growth

Steve Hirschfeld

Precision Medicine Group Board of Directors

Bill Theofilou

Managing Partner, Axia Ventures

Learn more about our leaders in clinical research and development at Precision for Medicine and in commercialization at Precision AQ

Precision for Medicine Leadership
Precision AQ Leadership